MM-1168: Belantamab Mafodotin, Bortezomib, and Dexamethasone vs Daratumumab, Bortezomib, and Dexamethasone in Relapsed/Refractory Multiple Myeloma: Updated 4-Year Results of the Phase 3 DREAMM-7 Trial
Year: 2026
Type: conference-abstract
Authors: Robert Rifkin, Vania Hungria, Marek Hus, Vera Zherebtsova, Christopher Ward, P Joy Ho, Angelo Maiolino, Roman Hájek, Kihyun Kim, Hanlon Sia, Adam Bryant, Marcelo Pitombeira de Lacerda, Anna Sureda, Benga Kazeem, Hena Baig, Nick Pirooz, Sybil Varghese, Joe Lee, Tom Jiang, Paweł Robak, María-Victoria Mateos, Al-Ola Abdallah
Institutions: University of Colorado Health, São Germano Oncologia, Medical University of Lublin, Botkin Hospital, Royal North Shore Hospital, The University of Sydney, Royal Prince Alfred Hospital, University of Ostrava, University Hospital Ostrava, Samsung Medical Center, Sungkyunkwan University, Liverpool Hospital, Universidade da Região de Joinville, Institut d'Investigació Biomédica de Bellvitge, Institut Català d'Oncologia, Universitat de Barcelona, GlaxoSmithKline (United Kingdom), GlaxoSmithKline (Canada), GlaxoSmithKline (United States), GlaxoSmithKline Research & Development Limited (United Kingdom), Medical University of Lodz, Universidad de Salamanca, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cáncer, Instituto de Biología Molecular y Celular del Cáncer de Salamanca, University of Kansas Medical Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W7204690948